Track topics on Twitter Track topics that are important to you
Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The companyâs products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladonâs first product candidate, MYDICARÂ®, delivers the gene for the SERCA2a enzyme and is currently being tested in Phase 1 and 2 clinical trials. Celladon is also developing traditional small molecule activators of SERCA2a for the treatment of heart failure. To learn more about Celladon, visit Celladonâs website at www.celladon.net.
2223 Avenida de la Playa #206
United States of America
NEW YORK, NY--(Marketwired - July 06, 2015) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celladon Corporation ("Celladon" or the "Company") (NASDAQ: CLDN) o...
NEW YORK, NY -- (Marketwired) -- 08/07/15 -- Pomerantz LLP announces that a class action lawsuit has been filed against Celladon Corporation ("Celladon" or the "Company") (NASDAQ: CLDN) and certai...
Eiger BioPharmaceuticals and Celladon agreed to merge into a single company, creating a combined firm with a diversified prod -More-
Celladon has issued a business update detailing its intention to suspend further development of its experimental…
Public firm Celladon Corp. is reverse merging with closely held Eiger BioPharmaceuticals, Inc.
Celladon has confirmed plans to suspend further R&D of its MYDICAR (AAV1/SERCA2a) program and its other preclinical programs, including the Stem Cell Factor (mSCF) gene therapy and SERCA2b small mole...
Celladon has officially thrown in the towel on its gene therapy work, telling investors on 26 June that the biotech has stopped work on all assets and is hoping to sell off everything, or liquidate.
(Reuters) - Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure.
Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatme...
Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in develop...
We have published hundreds of Celladon Corporation news stories on BioPortfolio along with dozens of Celladon Corporation Clinical Trials and PubMed Articles about Celladon Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celladon Corporation Companies in our database. You can also find out about relevant Celladon Corporation Drugs and Medications on this site too.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...